AAA
ANRO icon

Affinity Asset Advisors’s Alto Neuroscience ANRO Stock Holding History

Affinity Asset Advisors’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4M Buy
850,000
+350,000
+70% +$8.09M 1.01% 31
2026
Q1 		$11.2M Buy
+500,000
New +$9.27M 0.58% 44

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Affinity Asset Advisors's ANRO Position: Q2 2026 in Review

Affinity Asset Advisors increased its Alto Neuroscience (ANRO) stake by 70% in Q2 2026, buying an estimated $8.09M and bringing the position to 850,000 shares worth $22.4M. The position accounts for 1.01% of the portfolio, ranked #31.

Affinity Asset Advisors first reported a position in ANRO in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Affinity Asset Advisors held 850,000 shares of Alto Neuroscience worth $22.4M as of Q2 2026.
  • Affinity Asset Advisors bought 350,000 Alto Neuroscience shares in Q2 2026, an estimated $8.09M.
  • Alto Neuroscience made up 1.01% of Affinity Asset Advisors's portfolio in Q2 2026, its #31 holding.
  • Affinity Asset Advisors first reported a position in Alto Neuroscience in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.